Estudo da correlação entre a mutação do gene kras e fatores clínico-patológicos de doentes com câncer colorretal metastático.

• Ano de defesa: 2018
• Autor(a) principal: Zanatto, Renato Morato [UNIFESP]
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de São Paulo (UNIFESP)
• Palavras-chave em Português: Colorectal neoplasms; Gene frequency; Molecular target therapy; Neoplasias colorretais; Frequencia do gene; Terapia de alvo molecular; Oncogenes
• Link de acesso: https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=6483160; https://repositorio.unifesp.br/handle/11600/52435

Objective: To investigate the association of clinical and pathological features with the frequency and types of KRAS mutations in patients with metastatic colorectal cancer. Methods: Sixty-nine patients diagnosed with colorectal cancer between 2005 and 2014, who were either metastatic at the time of diagnosis or developed metastasis subsequently, were retrospectively analyzed. The direct sequencing and pyrosequencing techniques were related to KRAS exon 2. Since mutation diagnosis, its type was determined. Results: The mutation in KRAS was found in 30 patients (43.4%). The most frequent were c.35G> T (p.G12V, 33.3%), c.35G> A (p.G12D, 23.3%) both in codon 12 and c.38G> A (p.G13D, 23.3%) in codon 13. No correlation was found between the KRAS mutation and age (p = 0,646) or gender (p = 0,815). However, the mutated KRAS group presented a CEA level above 5 with a higher frequency (p = 0.048) and the mutation at codon 13 was associated with involvement of more than one metastatic site in the course of the disease (p = 0,029). Although the presence of the mutation was not related to the location of the primary tumor (p = 0,568), the colon disease was associated with worse overall survival compared with rectal disease (p = 0,009). Conclusion: The mutated KRAS group had higher levels of CEA at admission and the mutation at codon 13 was associated with involvement of more than one metastatic site in the course of the disease. Colon disease was associated with the worst overall survival.